2-butenoic acid for sale

Thirty-nine evaluable patients with squamous cell lung cancer treated with combination chemotherapy consisting of doxorubicin, Oncovin, bleomycin, cisplatin and cytembena. Objective responses were seen in 46 percent of patients. Patients with the disease had a rate of 56 percent response. Two of the four complete responses were verified endoscopically and histologically. The median survival was 37.6 and 26.3 weeks for patients with limited and extensive disease (p less than 0.05) and 29.9 weeks for the entire group. Haematological toxicities and gastrointestinal were moderate. There was a drug-related death due to sepsis and 2 reversible acute renal failure. The chemotherapeutic combination seems relatively effective. It causes a regression of the tumor, and possibly survival of responder patients with acceptable quality to increase. Maintenance chemotherapy with CCNU, cyclophosphamide, methotrexate, procarbazine be removed alternating with vinblastine, nitrogen mustard, methotrexate, procarbazine, often caused because of severe toxicity.